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CLINICAL TRIALS/CLINICAL STUDIES
Cystatin C and Baseline Renal Function Among
HIV-Infected Persons in the SUN Study
Edgar Turner Overton,1 Pragna Patel,2 Kristin Mondy,3 Tim Bush,2 Lois Conley,2 Frank Rhame,4,5
Erna Milunka Kojic,6 John Hammer,7 Keith Henry,5,8and John T. Brooks,2 for the SUN Study Investigators
Abstract
In the combination antiretroviral therapy (cART) era, renal dysfunction remains common. The Study to Un-
derstand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN) (ClinicalTrials.gov number,
NCT00146419) is a prospective observational cohort study of HIV-infected adults. At baseline, comprehensive
data were collected, including cystatin C and measures of renal function. Univariate and multivariate regression
analyses were performed to identify factors associated with baseline renal dysfunction [estimated glomerular
ﬁltration rate (eGFR) < 90ml/min/1.73m2 calculated using the simpliﬁed Modiﬁcation of Diet in Renal Disease
equation] and elevated cystatin C ( > 1.0mg/liter) in a cross-sectional analysis. Among 670 subjects with com-
plete data (mean age 41 years, mean CD4 cell count 530 cells/mm3, 79% prescribed cART), the mean eGFR was
96.8ml/min/1.73m2. Forty percent of subjects had renal dysfunction; 3.3% had chronic kidney disease (eGFR
< 60ml/min/1.73m2). Elevated cystatin C was present in 18% of subjects. In multivariate analysis, renal dys-
function was associated with older age, non-Hispanic white race/ethnicity, higher body mass index (BMI),
hypertension, higher cystatin C levels, and current prescription of ritonavir. Factors associated with elevated
cystatin C included hepatitis C coinfection, hypertension, current smoking, older age, current tenofovir use,
detectable plasma HIV RNA, and elevated microalbuminuria. The prevalence of chronic kidney disease (CKD)
was low in this contemporary HIV cohort. However, mild to moderate renal dysfunction was common despite
the widespread use of cART.
Introduction
In the era of combination highly active antiretroviraltherapy (cART), HIV infection has evolved into a man-
ageable chronic medical illness with reduced morbidity and
mortality for patients who remain engaged in care.1,2 During
the past decade, the incidence of HIV-associated nephropathy
(HIVAN), renal failure, and end-stage renal disease has de-
clined signiﬁcantly,3–7 primarily as a result of more wide-
spread use of cART. However, up to 30% of HIV-infected
patients have evidence of renal dysfunction.8 Additionally, a
variety of cART-related renal adverse events have been
noted, including proteinuria, renal tubular damage, intersti-
tial nephritis, and nephrolithiasis.9–14 Furthermore, other co-
morbidities such as hypertension, insulin resistance, obesity,
and type 2 diabetes, which are increasingly prevalent among
contemporary HIV-infected patients in care, may increase the
risk for renal dysfunction over time.15,16
In 2005, guidelines for screening and treating renal disease
in HIV-infected persons were published by the HIV Medical
Association of the Infectious Diseases Society of America.
These guidelines recommended that all HIV-infected patients
be screened annually for proteinuria and have their glomer-
ular ﬁltration rate (GFR) estimated using one of a number of
calculations based on serum creatinine and other clinical
factors.8,17 Creatinine-based equations are helpful to identify
persons with kidney disease, but serum creatinine may be
affected by factors other than glomerular ﬁltration, notably
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muscle mass, liver disease, dietary intake, age, race/ethnicity,
and gender.18 While the calculated equations account for
some of the effects of muscle mass, age, race/ethnicity, and
gender, they overestimate glomerular function for persons
with lower creatinine intake or production, as can occur in
persons with liver disease and possibly advanced HIV infec-
tion.18
Serum cystatin C, a small (13-kDa), nonglycosylated pro-
tein that is produced by all nucleated cells at a constant rate
and is exclusively cleared by glomerular ﬁltration, has been
proposed as an alternative marker of renal function.19–21 Re-
cent data illustrate that formulas utilizing serum cystatin C
provide GFR estimates equivalent to serum creatinine-based
measures that are not affected by muscle mass or decreased
creatinine production.22 The use of cystatin C is particularly
relevant for older populations and for persons with chronic
illnesses such as HIV infection.23,24 Several studies have ex-
amined cystatin C as a marker of kidney function in HIV-
infected persons25–27 and speciﬁcally proposed using serum
cystatin C as an alternative marker for renal impairment in
this population. In the present analysis, we evaluated renal
function of participants in a contemporary cohort of HIV-
infected patients treated only with cART or who were anti-
retroviral naive to describe the prevalence of and risk factors
associated with renal dysfunction and to examine the associ-
ation of elevated cystatin C levels with preclinical renal dys-
function in this population.
Materials and Methods
Participants
The SUN Study (ClinicalTrials.gov number, NCT00146419)
is a prospective, observational cohort study funded by the
Centers for Disease Control and Prevention (CDC) that
monitors the clinical course of HIV-infected adults treated
only with cART or who were antiretroviral naive. Patients
were enrolled at seven HIV specialty clinics in four U.S. cities:
St. Louis, Missouri; Providence, Rhode Island; Minneapolis,
Minnesota; and Denver, Colorado. The study’s main objec-
tives were to monitor the incidence of and identify risk factors
for metabolic and other medical complications related to the
treatment of HIV infection and attendant prolonged survival;
the detailed study protocol has been described elsewhere.28 In
brief, seven hundred HIV-infected adults were enrolled be-
tween March 2004 and June 2006 into a closed cohort. Eligible
participants were ‡ 18 years of age with conﬁrmed HIV in-
fection, had a CD4 count > 100 cells/mm3, and were either
antiretroviral naive or had been treated solelywith cARTwith
nomore than 30 days of cumulative exposure to anymono- or
dual-antiretroviral regimen; cARTwas deﬁned as the use of at
least three drugs from two different antiretroviral drug clas-
ses, or the use of three or more nucleoside reverse transcrip-
tion inhibitors (NRTIs). The current cross-sectional analysis
includes 670 subjects with complete data available at baseline.
Clinical and metabolic data collection
Comprehensive clinical and demographic data were col-
lected on all subjects at enrollment including past medical
history, all active diagnoses, results of all laboratory testing,
and type and duration of all prescribed medications. Many of
the clinical and laboratory data elements necessary for the
study were already collected as part of routine care. Addi-
tional study-speciﬁc laboratory testing included urinalysis
and spot measurement of urine microalbumin and creatinine.
Each subject completed an anonymous audio computer-
assisted self-interview to obtain behavioral risk data and other
health-related information including selected family history
variables and use of tobacco, alcohol, and recreational drugs.
Laboratory data were measured by commercial assay at each
site according to the care provider’s usual standard of care.
Fasting status (at least 8 h) was veriﬁed at the time of speci-
men collection.
Laboratory tests used for research purposes only [i.e.,
fasting insulin, highly-sensitive C-reactive protein (hsCRP),
25-hydroxyvitamin D, cystatin C] were performed by the
Diabetes Research and Training Center Radioimmunoassay
Core Laboratory, Washington University School of Medicine.
Serum and plasma used for these tests were iced and centri-
fuged at the time of blood draw then stored at - 70C until
time of batched assay. Methods for these assays were as fol-
lows: cystatin C was analyzed by an immunoturbidometric
assay using Dako reagents (Dakocytomation, Glostrup,
Denmark) on a Hitachi 917 analyzer (Roche Diagnostics,
Manheim, Germany); insulin was analyzed by radioimmu-
noassay using 125I-labeled tracer from Millipore (Millipore,
Billerica, MA); hsCRP was analyzed by a latex particle-
enhanced immunoturbidometric assay (Kamiya Biomedical
Company, Seattle, WA) on a Hitachi 917 analyzer; and vita-
min D was analyzed by a two-step radioimmunoassay (RIA)
(Diasorin Inc, Stillwater, MN).
Renal function
Using the recommendations of the National Kidney
Foundation,17 we deﬁned renal dysfunction as having an
eGFR < 90ml/min/1.73m2 and chronic kidney disease
(CKD) as an eGFR < 60ml/min/1.73m2 using the simpliﬁed
Modiﬁcation of Diet in Renal Disease (sMDRD) equation:
186· serum creatinine 1:154 · age 0:203
· 1:212 ðif African-AmericanÞ· 0:742 ðif female)
To explore the role of cystatin C as a marker of preclinical
renal dysfunction, we dichotomized cystatin C concentrations
and deﬁned an elevated cystatin C concentration as a serum
value of >1.0mg/liter. This level was selected based on the
upper limit of the normal reference range (0.55–1.41mg/liter)
for cystatin C29 aswell as previous data that have identiﬁed an
increased risk of mortality, cardiovascular events, and of
progression of kidney disease among persons with cystatin C
levels above this level.30–32
Statistical analysis
The outcome variables included eGFR < 90ml/min/
1.73m2 and eGFR < 60ml/min/1.73m2 calculated using the
sMDRD formula and serum cystatin C level > 1.0mg/liter.
Data were analyzed using the v2 or Fisher’s exact test for
categorical variables and Student’s t-test or the Mann–
Whitney U test for normally and nonnormally distributed
continuous variables, respectively. Univariate correlation
testing was used to test the strength of association between
renal dysfunction and other clinical variables. Variables were
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assessed for signiﬁcant interaction and redundant variables
were removed from the model. Multivariate logistic regres-
sion models were used to explore the associations with the
outcome variables. Variables with a p-value < 0.10 in bivariate
analysis were entered stepwise into regression models in or-
der to determine the most parsimonious multivariate model.
Age, race/ethnicity, and gender were included in all models
regardless of statistical signiﬁcance. All p-values were two-
tailed and considered signiﬁcant if the p-value was < 0.05. All
statistical analyses were performed using SAS, version 9.1
(SAS Institute, Inc., Cary, NC).
Results
Subject characteristics and prevalence
of renal dysfunction
At enrollment, among the 670 subjects for whom complete
evaluable data for the present analysis were available, most
were male (77%) and non-Hispanic white (59%, compared
with 29% non-Hispanic black, 10% Hispanic, and 2% Other/
unknown). The mean age was 41.0 years (Table 1) and the
mean time since HIV diagnosis was 6.1 years. Nadir and
baseline mean CD4 cell counts were 228 and 530 cells/mm3,
respectively. The majority of subjects (79%) were prescribed
cART, of whom89%had a plasmaHIVRNA < 400 copies/ml.
Overall, the mean eGFR by the sMDRD equation was
96.8ml/min/1.73m2. Forty percent of subjects had renal
dysfunction (eGFR < 90ml/min/1.73m2), but only 3.3% had
CKD (eGFR < 60ml/min/1.73m2). Eighty-one subjects (13%)
had proteinuria by urine dipstick and 69 subjects (11%) had
microalbuminuria (urine albumin > 30mg/dl). In univariate
analyses, persons with renal dysfunction were more likely to
be older (43.5 vs. 39.3 years, p < 0.001), to be of non-Hispanic
white race/ethnicity (65% vs. 55%, p = 0.040), to have higher
BMI (27.0 vs. 26.1 kg/m2, p = 0.066), to have hypertension
(39% vs. 26%, p < 0.001), to use an angiotensin-converting
enzyme (ACE) inhibitor or angiotensin receptor blocker
(ARB) (21% vs. 15%, p = 0.024), to have microalbuminuria
(15% vs. 8%, p = 0.005), to have higher mean hemoglobin (14.6
vs. 14.4 g/dl, p= 0.041), to have higher mean cystatin C levels
(0.94 vs. 0.87mg/liter, p< 0.001), and to have higher mean 25-
hydroxyvitamin D levels (27.0 vs. 23.0, p< 0.001). In univari-
ate analyses, persons with renal dysfunction were less likely
to be current smokers (39% vs. 47%, p= 0.035) or intravenous
drug users (1% vs. 3%, p= 0.031). The following HIV-related
parameters were also associated with renal dysfunction in
univariate analysis: currently taking tenofovir (46% vs. 36%,
p = 0.013) or ritonavir (any dose) (39%vs. 24%, p < 0.01) or both
(23% vs. 14%, p < 0.001) and having controlled HIV viremia
(HIV RNA < 400 copies/ml) (77% vs. 70%, p = 0.027). In
multivariate analysis, the following parameters remained in-
dependently associated with renal dysfunction: older age,
non-Hispanic white race/ethnicity, higher BMI, having hy-
pertension, higher cystatin C levels, and current prescription
of ritonavir (Table 2).
Factors associated with CKD (eGFR < 60ml/min/1.73m2)
in univariate analysis included older age (48.0 vs. 40.7 years,
p < 0.001), female gender (45% vs. 23%, p= 0.012), non-
Hispanic black race/ethnicity (59% vs. 28%, p = 0.016), higher
BMI (29.2 vs. 26.4 kg/m2, p= 0.029), hypertension (77%
vs. 29%, p < 0.001), receipt of an ARB/ACE inhibitor (45%
vs. 17%, p= 0.002), chronic HCV infection (32% vs. 13%,
p = 0.010), microalbuminuria (24% vs. 10%, p = 0.043), elevated
mean cystatin C (1.20 vs. 0.89mg/liter, p < 0.001), lower nadir
CD4 cell count (123 vs. 230 cells/mm3, p= 0.002), history of an
opportunistic infection (50% vs. 22%, p = 0.002), and currently
taking cART (100% vs. 78%, p= 0.007), speciﬁcally ritonavir
(50% vs. 29%, p= 0.039). Because of the small number of pa-
tients (n = 22) with CKD, a multivariate analysis was not
conducted.
Cystatin C results
Eighteen subjects did not have an evaluable stored sample
for cystatin C measurement. Among the remaining 652 sub-
jects who had complete baseline data and cystatin C results,
themean cystatin C level was 0.90 – 0.01mg/liter. Therewas a
signiﬁcant correlation between cystatin C and eGFR as cal-
culated using the sMDRD equation and between cystatin C
and urine albumin levels (r = –0.35 and 0.14, respectively,
p < 0.001 for both; see Figs. 1 and 2). One hundred and twenty
subjects (18%) had a cystatin C level > 1.0mg/liter. In uni-
variate analysis, persons with an elevated cystatin C level
were older (42.9 vs. 40.6 years, p= 0.008), more likely to be
hypertensive (41% vs. 28%, p= 0.007), to be prescribed an
ARB/ACE inhibitor (25% vs. 16%, p = 0.016), to currently
smoke tobacco (61% vs. 40%, p < 0.001), to have viral hepatitis
C (HCV) (29% vs. 10%, p< 0.001) or chronic viral hepatitis B
coinfection (9% vs. 4%, p = 0.023), to have lower mean hemo-
globin (14.0 vs. 14.6 g/dl, p= 0.001), lower mean total cho-
lesterol (177 vs. 187mg/dl, p = 0.027), lower LDL cholesterol
(100 vs. 111mg/dl, p= 0.005), and to have microalbuminuria
(20% vs. 8%, p < 0.001). These patients also had lower baseline
CD4 cell counts (453 vs. 547 cells/mm3, p< 0.001), were less
likely to have an undetectable HIV viremia ( £ 400 copies/ml)
(60% vs. 76%, p < 0.001), were less likely to be prescribed cART
(72% vs. 81%, p= 0.029), and were prescribed cART for a
shorter mean duration (2.3 vs. 3.1 years, p< 0.001).
For subjects prescribed cART, elevated cystatin C was as-
sociated with current exposure to tenofovir (49% vs. 38%,
p = 0.026). In multivariate analysis, elevated cystatin C re-
mained associated with older age, HCV coinfection, current
tobacco smoking, current use of tenofovir, and micro-
albuminuria. Longer duration of cART and undetectable viral
load were associated with lower levels of cystatin C (Table 2).
Discussion
Overall, these data conﬁrm that end stage renal disease and
chronic kidney disease are less common in the cART era
among HIV-infected persons who are engaged in care.5–7
Nevertheless, impairment in renal function is of growing
importance as comorbidities such as diabetes, hypertension,
and atherosclerosis are becomingmore prominent in the long-
termmanagement of HIV disease.33,34While the prevalence of
renal dysfunction (eGFR < 90ml/min/1.73m2) was high
(40.3%) in this cohort, CKD (eGFR < 60ml/min/1.73m2) was
uncommon (3.3%), similar to other reported cohorts with ac-
cess to cART.7 Factors associated with renal dysfunction in-
cluded traditional risk factors (e.g., older age, hypertension,
elevated BMI), as well as current exposure to ritonavir and
non-Hispanic white race/ethnicity. This latter association
might have resulted from the effect of the race-based correc-
tion factor used in the sMDRD formula. Notably, when we
focused our analysis on subjects with CKD (eGFR < 60ml/
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min/1.73m2), non-Hispanic black race/ethnicity was associ-
ated with more advanced renal dysfunction, as expected.
Concern has been raised about the inherent bias of using
creatinine-based formulas to estimate GFR for populations
enriched in patients with chronic medical conditions such as
HIV infection.35,36 Notably, GFR estimation formulas have
not been formally validated for HIV-infected adults. Several
studies have assessed the utility of cystatin C as an alternative
measure of glomerular ﬁltration and found it to perform as
well as, if not better, than creatinine-based formulas.22,37–39 In
theModiﬁcation of Diet in Renal Disease (MDRD) Study, both
cystatin C levels and serum creatinine were highly correlated
Table 1. Characteristics of SUN Study Participants
Characteristic Overall cohort (n= 670)
Age, years, mean (SEM) 41.0 (0.34)
Male gender, n (%) 514 (77)
Race, n (%)
White 395 (59)
Black 195 (29)
Hispanic 65 (10)
Other 15 (2)
BMI, kg/m2, mean (SEM) 26.5 (0.23)
Hypertension, n (%) 207 (31)
Diabetes, n (%) 29 (4)
ACE/ARB use, n (%) 117 (17)
Current smoking, n (%) 291 (43)
Current intravenous drug use, n (%) 15 (2)
Chronic viral hepatitis, n (%)
Hepatitis C (n = 662) 89 (13)
Hepatitis B (n= 651) 31 (5)
Proteinuria (n = 641), n (%) 81 (13)
Glucosuria (n= 626), n (%) 6 (1)
Presence of spot urine albumin > 30mg/dl (n= 657), n (%) 69 (11)
Hemoglobin, g/dl (n = 666), mean (SEM) 14.5 (0.06)
Glucose, mg/dl (n = 666), mean (SEM) 94.7 (0.92)
hsCRP, lg/liter (n = 652), mean (SEM) 4.3 (0.31)
Cystatin C, mg/liter (n= 652), mean (SEM) 0.90 (0.01)
Total cholesterol, mg/dl, mean (SEM) 185 (1.72)
LDL cholesterol, mg/dl, mean (SEM) 109 (1.47)
HDL cholesterol, mg/dl, mean (SEM) 43 (0.58)
Triglycerides, mg/dl, mean (SEM) 175 (5.43)
Insulin, lU/ml, mean (SEM) 12.1 (0.67)
25-Hydroxyvitamin D, ng/ml, mean (SEM) 24.6 (0.47)
HIV-associated variables
Time since HIV diagnosis, years, mean (SEM) 6.1 (0.19)
Nadir CD4 cell count, cells/mm3, mean (SEM) 228 (6.50)
Baseline CD4 cell count, cells/mm3 (n = 667), mean (SEM) 530 (10.67)
HIV RNA < 400 copies/ml (n = 669), n (%) 487 (73)
Currently on HAART, n (%) 530 (79)
Duration of HAART, years, mean (SEM) 3.0 (0.10)
History of AIDS-deﬁning opportunistic infection, n (%) 155 (23)
History of CD4 cell count < 200 cells/mm3, n (%) 320 (48)
Current antiretroviral HIV treatment, n (%)
Tenofovir 267 (40)
Ritonavir (including as PI boosting agent) 202 (30)
Tenofovir and ritonavir use 116 (17)
Atazanavir 95 (14)
Indinavir use 4 (1)
Efavirenz 175 (26)
Nevirapine 84 (13)
Lamivudine 331 (49)
Zidovudine 221 (33)
Abacavir 141 (21)
Didanosine 31 (5)
Stavudine 30 (4)
Current renal-toxic drug usea 71 (11)
aIncludes acyclovir, pentamidine, foscarnet, cidofovir, or amphotericin B.
ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker inhibitor; BMI, body mass index; CRP, C-reactive
protein; HAART, highly active antiretroviral therapy; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PI, protease inhibitor.
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with glomerular ﬁltration estimates by iothalamate renal
clearance, but only cystatin Cwas signiﬁcantly associatedwith
mortality endpoints.38 The authors concluded that serum cy-
statin C levels better reﬂected renal function independent of
confounding factors such as systemic inﬂammation or
weight.38 Given the recent use of the CKD-EPI formula,we also
evaluated the correlation between eGFR calculated by the
sMDRD andCKD-EPI formulas and found a strong correlation
(Spearman correlation r= 0.94, p< 0.001) suggesting that the
two formulas produce similar results in this cohort. Never-
theless, there is growing support for the use of CKD-EPI, par-
ticularly in persons with eGFR > 60ml/min/1.73m2.40,41
Our multivariate analyses demonstrated that factors tra-
ditionally associated with renal disease were also associated
with elevated cystatin C ( > 1.0mg/liter), such as hyperten-
sion, tobacco smoking, older age, and viral hepatitis C coin-
fection. Among HIV-speciﬁc risks, current use of tenofovir
was also associated with elevated levels of serum cystatin C
while longer duration of cART and controlled HIV viremia
(plasma HIV RNA < 400 copies/ml) were associated with
decreased levels of serum cystatin C. The relationship with
both chronic HCV infection and uncontrolled HIV viremia
raises the concern as to whether elevated cystatin C is a
marker of renal function or ongoing inﬂammation as a con-
sequence of chronic viremia. Additional research is needed to
explore these ﬁndings. Furthermore, the correlation between
cystatin C and eGFR was signiﬁcant but modest, suggesting
that there are other factors that may better explain renal
dysfunction. The fact that tenofovir use was associated with
elevated cystatin C but not reduced creatinine clearance is also
worthy of further study given that cystatin C may serve as a
marker of preclinical renal disease.42 This is particularly
warranted given the expanding use of tenofovir for the
treatment of hepatitis B infection and as a component of
preexposure prophylaxis for HIV infection.43,44
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FIG. 2. Correlation between cystatin C and urine albumin
level. Spearman’s rank correlation was performed. Micro-
albumin data were square root transformed to account for
nonnormal distribution.
Table 2. Factors Associated with Renal Dysfunction and Increased Cystatin C Levels
Univariate results Multivariate resultsa
Characteristics Odds ratio (95% CI) p-value Adjusted odd ratios (95% CI) p-value
Factors associated with renal dysfunction (sMDRD GFR < 90ml/min/1.73m2)
Age > 35 years old 3.46 (2.33–5.26) <0.001 3.27 (2.13–5.12) <0.001
White race 1.55 (1.13–2.13) 0.007 1.54 (1.09–2.20) 0.015
Body mass Index (BMI) > 25 kg/m2 1.45 (1.06–1.98) 0.020 1.43 (1.02–2.01) 0.041
Hypertension 1.81 (1.30–2.52) <0.001 1.52 (1.06–2.18) 0.024
Cystatin > 1.0mg/liter 2.30 (1.54–3.44) <0.001 2.03 (1.33–3.11) 0.001
Current use of low-dose ritonavir 1.93 (1.38–2.71) <0.001 2.17 (1.51–3.12) <0.001
Factors associated with increased cystatin levels (cystatin C >1.0mg/liter)
Age > 35 years old 1.73 (1.07–2.92) 0.031 2.03 (1.18–3.64) 0.013
Hepatitis C infection 3.57 (2.18–5.80) <0.001 2.47 ( 1.43–4.22) 0.001
Current tobacco smoker 2.34 (1.57–3.53) <0.001 2.06 (1.32–3.21) 0.001
Current use of tenofovir 1.57 (1.05–2.34) 0.027 1.90 (1.20–3.04) 0.006
Urine albumin > 30mg/dl 2.67 (1.52–4.60) <0.001 2.31 (1.26–4.17) 0.006
Duration of cART prescription (none, < 2 years, ‡ 2 years) 0.62 (0.47–0.82) <0.001 0.64 (0.46–0.89) 0.009
Viral load < 400 copies/ml 0.47 (0.31–0.71) <0.001 0.50 (0.30–0.84) 0.009
aAge, race/ethnicity, and gender were included in all models regardless of statistical signiﬁcance.
CI, conﬁdence interval; sMDRD, simpliﬁed Modiﬁcation of Diet in Renal Disease; GFR, glomerular ﬁltration rate; cART, combination
antiretroviral therapy.
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The relationship between uncontrolled HIV viremia and
renal dysfunction has been noted in other research, most no-
tably a recently published study.45 In that study, subjects who
followed a treatment interruption strategy were at higher risk
of developing fatal or nonfatal renal disease when compared
with patients randomized to continue antiretroviral therapy
without interruption. In subsequent analyses from the same
trial, it was reported that treatment interruption was also
associated with elevated levels of cystatin C. 27,46 The authors
suggested that this increase was likely related to direct viral
toxicity on the renal tubule rather than the overall inﬂam-
matory milieu associated with poorly controlled HIV infec-
tion, although the local injury is potentially mediated by
inﬂammation as suggested in several other published reports
both in HIV-infected and HIV-negative subjects.27,47–49 Fur-
ther evaluations of the role of cystatin C and its correlation
with and regulation by inﬂammatory cytokines will improve
the utility of this protein as a marker of renal function.50,51
Clearly, there remains the need to further evaluate the utility
of cystatin C as a marker of renal function. For the current
cohort, we determined the threshold of cystatin C > 1.0mg/
liter had a positive predictive value of only 0.57 and 0.12 for
eGFR < 90 and < 60ml/min/1.73m2, respectively, and a
negative predictive value of 0.64 and 0.99 for eGFR < 90 and
< 60ml/min/1.73m2, respectively (data not shown). These
data suggest that the use of cystatin C alone lacks adequate
sensitivity for an effective screening test.
Urine dipsticks and spot urine microalbumin quantiﬁca-
tion, which are used extensively in the management of dia-
betes, can also provide the HIV practitioner with a means to
monitor renal function and screen for incipient preclinical
dysfunction potentially related to chronic HIV infection, its
treatment, or concomitant comorbidities such as hyperten-
sion or diabetes. Overall, 13% of the SUN cohort had at least
trace proteinuria by urinary dipstick and 11% had micro-
albuminuria, which was microalbuminuria was associated
with elevated cystatin C levels. Considering the relatively
inexpensive cost of spot urine microalbumin quantiﬁcation,
its integration into the routine care of HIV warrants further
evaluation. Given that elevated cystatin C was also associ-
ated with renal dysfunction, further research is needed to
identify cystatin C criteria that equate to various degrees
of renal function by a gold standard such as iothalamate
clearance.
Our analysis has a number of important limitations. It was
cross-sectional and therefore limited in its ability to discern
generalizable associations as well as to evaluate changes in
renal function over time. Longitudinal follow-up will provide
greater insight into the ﬁndings reported here. We cannot
generalize our ﬁndings from this cohort to all HIV-infected
patients; however, we believe our data are relevant to the care
of contemporary and future patients in developed nations for
many of whomHIVwill be a chronic medical condition. Also,
our treatment data are limited to prescribed medications and
we do not have complete data on over-the-counter therapies,
most notably nonsteroidal antiinﬂammatory medications, the
use of which can contribute to renal dysfunction. The utility of
cystatin C among HIV-infected subjects, speciﬁcally with re-
gards to the relationship with inﬂammation and chronic viral
infections and the mechanism by which it is increased in both
renal disease and inﬂammatory states, requires further clari-
ﬁcation beyond the scope of the present analysis.
In conclusion, the prevalence of CKDwas low in this cohort
of contemporaryHIV-infected patients; however, a signiﬁcant
proportion of persons had preclinical renal dysfunction that
might have negative long-term implications for future renal
function and other parameters. We found that elevated cy-
statin C, a marker for preclinical renal dysfunction, was
common and strongly associated with ongoing HIV viremia,
a ﬁnding that suggests that the beneﬁts of cART-associated
virologic suppression go beyond immune reconstitution. In-
dependent associations with modiﬁable risk factors, includ-
ing hypertension, smoking, and hepatitis C coinfection,
indicate that there are additional opportunities for prevention
of renal disease. Further studies are warranted to explore the
utility of cystatin C and the impact of cART on the prevention
of end-organ disease.
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